Annexon, Inc. Common StockANNX
Scheduled
Annexon, Inc. Common Stock 12th Annual Cantor Fitzgerald Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
PeriodFY 0
Key takeaways
- Anexon is a complement-focused biotech company targeting neuroinflammation in the body, brain, and eye, with two late-stage programs: one in Guillain-Barré syndrome (GBS) and one in geographic atrophy (GA).
- The GA program demonstrated significant vision preservation in a phase II Archer study, showing dose-dependent functional benefit on best corrected visual acuity (15-letter loss) and low luminous visual acuity, with a 73% reduction in risk of greater than 15-letter loss at 12 months.
- The phase II study showed a trend but not statistically significant reduction in RPE lesion growth, while demonstrating significant preservation of photoreceptor neurons, measured by ellipsoid zone (EZ), which is a more meaningful marker of retinal health and vision preservation.
- The phase III Archer II study is underway with 659 patients randomized 2:1 to Von Approval versus sham, with dual primary endpoints at month 15 and month 24 assessing confirmed 15-letter vision loss.
- The study excluded patients with very poor vision below 45 letters based on phase II learnings and has a dropout rate of less than 10% and compliance rate greater than 90%.
- Von Approval’s mechanism of action is C1Q inhibition, which specifically protects photoreceptor synapses, differentiating it from other complement inhibitors that target downstream pathways.
- The company is preparing for a 4Q26 data monitoring committee (DMC) review of the month 15 endpoint with potential unmasking and filing if positive; otherwise, the study will continue blinded to month 24 for safety and efficacy assessment.
- The GBS program showed a 100% response rate at week one in open-label data, consistent with prior phase III results, supporting regulatory filings in the EU and planned FDA filing by year-end.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Keep exploring